AI Article Synopsis

  • SETD2 and BAP1 are chromatin remodeling genes that are frequently mutated in clear cell renal cell carcinoma (ccRCC) and play a role in tumor progression and metastasis.
  • A study compared 7 cases of locally advanced ccRCC with SETD2 mutations to 7 cases with BAP1 mutations, finding that SETD2-mutated tumors exhibited aggressive growth with a rhabdoid morphology and significant invasive characteristics.
  • The study emphasizes the importance of molecular testing for SETD2 and BAP1 mutations in ccRCC for better risk assessment and treatment strategies, as their high-grade features can overlap, making it challenging to identify the mutations based solely on tumor appearance.

Article Abstract

SET-domain containing 2 (SETD2) and BRCA1-associated protein 1 (BAP1), both chromatin remodeling genes, are frequently mutated in clear cell renal cell carcinoma (ccRCC) and involved in tumor progression and metastasis. Herein, we studied clinicopathologic features of 7 cases of locally advanced ccRCC with single SETD2 mutation, and compared to 7 cases of locally advanced ccRCC with single BAP1 mutation. SETD2-mutated ccRCC showed high-grade transformation, comprising of enlarged tumor cells with voluminous clear cytoplasm, enlarged irregular nuclei with prominent nucleoli, eosinophilic cytoplasmic granules, arranged in various architectural patterns such as large nested, tubular, tubulopapillary and solid. 71 % (5 of 7 cases) of SETD2-mutated ccRCC showed a rhabdoid morphology. SETD2-mutated ccRCC have striking propensity for invasive growth; all cases have vascular invasion and perirenal (extracapsular) adipose tissue invasion. After nephrectomy, distant metastasis was found in 67 % (4 of 7 cases) of patients with SETD2-mutated ccRCC. The most common metastatic site was the lung (3 cases), followed by precaval lymph nodes (1 case). BAP1-mutated ccRCC also showed a similar high-grade morphology, with rhabdoid and/or sarcomatoid features. Their high-grade features mostly overlapped with those of SETD2-mutated ccRCC, which makes difficult to predict the presence of BAP1 or SETD2 mutation solely from morphology. These findings justify the use of molecular testing to detect these mutations, especially when we encounter high-grade ccRCC. Detecting SETD2 and BAP1 mutation in ccRCC is useful for risk stratification and proper therapeutic strategy.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.anndiagpath.2023.152223DOI Listing

Publication Analysis

Top Keywords

setd2-mutated ccrcc
20
locally advanced
12
clear cell
12
cell renal
12
renal cell
12
cell carcinoma
12
ccrcc
11
cases locally
8
advanced ccrcc
8
ccrcc single
8

Similar Publications

Background: Renal cell carcinoma (RCC) is the most prevalent type of malignant kidney tumor in adults, with clear cell renal cell carcinoma (ccRCC) comprising about 75% of all cases. The SETD2 gene, which is involved in the modification of histone proteins, is often found to have alterations in ccRCC. Yet, our understanding of how these SETD2 mutations affect ccRCC characteristics and behavior within the tumor microenvironment is still not fully understood.

View Article and Find Full Text PDF
Article Synopsis
  • SETD2 and BAP1 are chromatin remodeling genes that are frequently mutated in clear cell renal cell carcinoma (ccRCC) and play a role in tumor progression and metastasis.
  • A study compared 7 cases of locally advanced ccRCC with SETD2 mutations to 7 cases with BAP1 mutations, finding that SETD2-mutated tumors exhibited aggressive growth with a rhabdoid morphology and significant invasive characteristics.
  • The study emphasizes the importance of molecular testing for SETD2 and BAP1 mutations in ccRCC for better risk assessment and treatment strategies, as their high-grade features can overlap, making it challenging to identify the mutations based solely on tumor appearance.
View Article and Find Full Text PDF

Background: SET domain-containing protein 2 () is commonly mutated in renal cell carcinoma. SETD2 methylates histone H3 as well as a growing list of non-histone proteins.

Objective: Initially, we sought to explore SETD2-dependent changes in lysine methylation of proteins in proximal renal tubule cells.

View Article and Find Full Text PDF
Article Synopsis
  • * Using data from major cancer databases, researchers identified the inhibitors TGX221 and AZD6482, with AZD6482 showing effectiveness against ccRCC with SETD2 mutations while also targeting additional mutations.
  • * Research results suggested that AZD6482 selectively inhibits harmful cancer cell behaviors, like migration and invasion, and may engage complex gene interactions, highlighting its high selectivity for ccRCC with SETD2 mutations.
View Article and Find Full Text PDF

Several novel recurrent mutations of histone modifying and chromatin remodeling genes have been identified in renal cell carcinoma. These mutations cause loss of function of several genes located in close proximity to VHL and include PBRM1, BAP1 and SETD2. PBRM1 encodes for BAF180, a component of the SWI/SNF chromatin remodeling complex, and is inactivated in, on average, 36% of clear cell renal cell carcinoma (ccRCC).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!